APPLICATION
ANDA212299
TYPE
ANDA
ORIGINAL APPROVAL
2020-09-10
LATEST ACTION
2025-01-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE, LIPOSOMAL
MARKETING STATUS
Prescription
Products
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 20MG/10ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
Approval history
2025-01-03Labeling · Supplement 7 · standardAP
2020-09-10UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.